Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002921 · ClinicalTrials.gov registry record · Phase 2
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00002921 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 13 participants.
The verdict
NCT00002921, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
Interventions
- DRUG therapeutic hydrocortisone
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1997-03 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002921
The ClinicalTrials.gov registry entry for NCT00002921 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which therapeutic hydrocortisone is the first listed.
NCT00002921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002921 about?
NCT00002921 is a clinical study titled "S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery". RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
What is the current status of trial NCT00002921?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 1997-03. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00002921?
The interventions under investigation include: therapeutic hydrocortisone (DRUG), suramin (DRUG).
Who is sponsoring clinical trial NCT00002921?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.